{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:57:13Z","timestamp":1782269833687,"version":"3.54.5"},"reference-count":24,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,10,11]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>We report a combination therapy to successfully treat a patient with Hodgkin\u2019s lymphoma complicated by vanishing bile duct syndrome. Our patient was in his 20s and presented with jaundice, emesis, B symptoms and diffuse lymphadenopathy along with cholestatic liver injury prompting a liver biopsy, which revealed this diagnosis, after the exclusion of other aetiologies. Our treatment regimen incorporated brentuximab along with other more conventional agents which attempted to maximise therapeutic efficacy while minimising the consequences of hepatotoxicity on the treatment protocol. Although this patient\u2019s treatment course was complicated because of neutropenic infections, the patient achieved a complete metabolic response and is now more than 1\u2009year off therapy.<\/jats:p>","DOI":"10.1136\/bcr-2023-257211","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:40:41Z","timestamp":1700570441000},"page":"e257211","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen"],"prefix":"10.1136","volume":"16","author":[{"given":"Judah D","family":"Morgan","sequence":"first","affiliation":[{"name":"Internal Medicine, Madigan Army Medical Center, Tacoma, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C","family":"Weishar","sequence":"additional","affiliation":[{"name":"Medicine, Uniformed Services University of the Health Sciences F Edward Hebert School of Medicine, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M","family":"Kwok","sequence":"additional","affiliation":[{"name":"Hepatology, Madigan Army Medical Center, Tacoma, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M","family":"Lieuw","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Madigan Army Medical Center, Tacoma, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"2025082713124769000_16.11.e257211.1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(61)90067-5"},{"key":"2025082713124769000_16.11.e257211.2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(93)90194-R"},{"key":"2025082713124769000_16.11.e257211.3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1080\/02841860701644078","article-title":"Hodgkin Lymphoma- related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review","volume":"47","author":"Ballonoff","year":"2008","journal-title":"Acta Oncologica"},{"key":"2025082713124769000_16.11.e257211.4","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab Vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082713124769000_16.11.e257211.5","doi-asserted-by":"crossref","unstructured":"Reau NS , Jensen DM . Vanishing bile duct syndrome. Clinics in Liver Disease 2008:203\u201317. doi:10.1016\/j.cld.2007.11.007","DOI":"10.1016\/j.cld.2007.11.007"},{"key":"2025082713124769000_16.11.e257211.6","doi-asserted-by":"publisher","DOI":"10.1007\/s005340170002"},{"key":"2025082713124769000_16.11.e257211.7","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.3748\/wjg.v12.i22.3523","article-title":"Heterogeneity of the Intrahepatic biliary epithelium","volume":"12","author":"Glaser","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025082713124769000_16.11.e257211.8","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","article-title":"Drug-induced bile duct injury","volume":"1864","author":"Visentin","year":"2018","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"2025082713124769000_16.11.e257211.9","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90102-7"},{"key":"2025082713124769000_16.11.e257211.10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i2.366"},{"key":"2025082713124769000_16.11.e257211.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.06.010"},{"key":"2025082713124769000_16.11.e257211.12","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000336","article-title":"Vanishing bile duct syndrome preceding the diagnosis of Hodgkin lymphoma","volume":"7","author":"Anugwom","year":"2020","journal-title":"ACG Case Rep J"},{"key":"2025082713124769000_16.11.e257211.13","doi-asserted-by":"crossref","unstructured":"Gaudel P , Brown P , Byrd K , et al . Vanishing bile duct syndrome in the presence of Hodgkin lymphoma. Cureus July 14, 2022. doi:10.7759\/cureus.26842","DOI":"10.7759\/cureus.26842"},{"key":"2025082713124769000_16.11.e257211.14","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1097\/MPH.0000000000002223","article-title":"Hodgkin lymphoma\u2013related vanishing bile duct syndrome cholestasis resolved after chemotherapy","volume":"44","author":"Gonzalez","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082713124769000_16.11.e257211.15","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1097\/MPH.0000000000002505","article-title":"Vanishing bile duct syndrome secondary to Hodgkin lymphoma in a child","volume":"44","author":"Palla Velangini","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082713124769000_16.11.e257211.16","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-529"},{"key":"2025082713124769000_16.11.e257211.17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227676","article-title":"Brentuximab Vedotin in combination with sequential Procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure","volume":"12","author":"Fong","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025082713124769000_16.11.e257211.18","doi-asserted-by":"crossref","unstructured":"Gupta A , Petrasek J , Sen S , et al . Single agent Brentuximab as bridging therapy for Hodgkin lymphoma patients with hepatic impairment. Blood 2015;126. doi:10.1182\/blood.V126.23.5105.5105","DOI":"10.1182\/blood.V126.23.5105.5105"},{"key":"2025082713124769000_16.11.e257211.19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3960\/jslrt.21035","article-title":"Administration of Brentuximab Vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events","volume":"62","author":"Ishitsuka","year":"2022","journal-title":"J Clin Exp Hematop"},{"key":"2025082713124769000_16.11.e257211.20","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12462"},{"key":"2025082713124769000_16.11.e257211.21","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1080\/10428194.2019.1579321","article-title":"Acute liver injury leading to death in the setting of Brentuximab Vedotin monotherapy","volume":"60","author":"Neeman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025082713124769000_16.11.e257211.22","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.3748\/wjg.v12.i22.3487","article-title":"Ursodeoxycholic acid treatment of vanishing bile duct syndromes","volume":"12","author":"Pusl","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025082713124769000_16.11.e257211.23","unstructured":"Fanale MA , Whiting NC , Neylon E . Treatment strategies to optimize outcomes with Brentuximab Vedotin: management of common and rare toxicities. J Target Ther Cancer 2015;4."},{"key":"2025082713124769000_16.11.e257211.24","doi-asserted-by":"crossref","unstructured":"Lai C , Kandahari AM , Ujjani C . The evolving role of Brentuximab Vedotin in classical Hodgkin lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 2019.","DOI":"10.2147\/BLCTT.S231821"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-257211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:12:56Z","timestamp":1756325576000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-257211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,21]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bcr-2023-257211"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-257211","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}